Swiss National Bank Has $37.63 Million Stake in Neurocrine Biosciences, Inc. $NBIX

Swiss National Bank raised its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 4.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 299,400 shares of the company’s stock after acquiring an additional 13,900 shares during the quarter. Swiss National Bank owned approximately 0.30% of Neurocrine Biosciences worth $37,632,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geneos Wealth Management Inc. lifted its stake in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the last quarter. WPG Advisers LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter worth $32,000. SVB Wealth LLC bought a new position in shares of Neurocrine Biosciences in the 1st quarter valued at $35,000. True Wealth Design LLC boosted its holdings in shares of Neurocrine Biosciences by 1,215.4% during the 2nd quarter. True Wealth Design LLC now owns 342 shares of the company’s stock valued at $43,000 after acquiring an additional 316 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in Neurocrine Biosciences by 6,285.7% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 447 shares of the company’s stock worth $49,000 after acquiring an additional 440 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Stock Down 0.4%

NBIX opened at $141.25 on Tuesday. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $157.67. The company has a fifty day moving average of $142.39 and a 200-day moving average of $134.15. The stock has a market cap of $14.08 billion, a PE ratio of 33.79, a price-to-earnings-growth ratio of 0.94 and a beta of 0.22.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The business had revenue of $794.90 million for the quarter, compared to analyst estimates of $746.61 million. During the same quarter in the previous year, the business earned $1.81 earnings per share. Neurocrine Biosciences’s revenue for the quarter was up 27.8% on a year-over-year basis. Sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 18,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total value of $2,732,760.00. Following the completion of the sale, the director directly owned 40,360 shares in the company, valued at approximately $6,127,455.20. The trade was a 30.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kyle Gano sold 300 shares of the stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total value of $42,591.00. Following the transaction, the chief executive officer owned 140,407 shares in the company, valued at $19,933,581.79. The trade was a 0.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Needham & Company LLC lifted their price target on Neurocrine Biosciences from $170.00 to $184.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Wednesday, October 8th. Stifel Nicolaus boosted their target price on shares of Neurocrine Biosciences from $174.00 to $183.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Citigroup raised their price target on shares of Neurocrine Biosciences from $175.00 to $203.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Neurocrine Biosciences from $171.00 to $179.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $170.53.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.